Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
BHV-2100 by Biohaven for Migraine: Likelihood of Approval
BHV-2100 is under clinical development by Biohaven and currently in Phase II for Migraine. According to GlobalData, Phase II drugs...
Data Insights
BHV-2100 by Biohaven for Neuropathic Pain (Neuralgia): Likelihood of Approval
BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase...